Recruiting NA Type 2 Diabetes Mellitus (T2DM)

New treatment option for Type 2 Diabetes Mellitus (T2DM)

Official title Effects of Short and Long Courses of Intermittent Hypoxic-Hyperoxic Training in Patients With Type 2 Diabetes Including Elderly

ClinicalTrials.gov ID: NCT07574333

What this study is testing

What it's testing
This is a single-center randomized controlled trial evaluating the efficacy and safety of short (3 days) versus long (10 days) courses of intermittent hypoxic-hyperoxic training (IHHT) in patients with type 2 diabetes mellitus aged 50-74 years. Participants will be randomized into three groups: 3-day IHHT course (n≥100), 10-day IHHT course (n≥100), or control group receiving gas mixture with constant O2 21% for 10 days (n≥50).
  • Which group you join is decided by chance.

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 50 to 74

You may be able to join if

  • Age 50-74 years inclusive
  • Type 2 diabetes mellitus confirmed by medical documentation
  • Stable therapy for diabetes and other chronic diseases for at least 4 weeks prior to enrollment
  • Ability to comply with study protocol requirements
  • Signed informed consent

You likely can't join if

  • Type 1 diabetes mellitus
  • Acute diabetes complications within 6 months (diabetic ketoacidosis, hyperosmolar hyperglycemic state, lactic acidosis, hypoglycemic coma)
  • Acute or active chronic infections
  • Angina pectoris functional class III-IV
  • Uncontrolled grade 3 arterial hypertension (SBP ≥180 and/or DBP ≥110 mmHg)
  • Acute cerebrovascular accident, myocardial infarction, surgical interventions, clinically significant injuries within 6 months
See the full eligibility criteria
Who can join
  • Age 50-74 years inclusive
  • Type 2 diabetes mellitus confirmed by medical documentation
  • Stable therapy for diabetes and other chronic diseases for at least 4 weeks prior to enrollment
  • Ability to comply with study protocol requirements
  • Signed informed consent
What rules you out
  • Type 1 diabetes mellitus
  • Acute diabetes complications within 6 months (diabetic ketoacidosis, hyperosmolar hyperglycemic state, lactic acidosis, hypoglycemic coma)
  • Acute or active chronic infections
  • Angina pectoris functional class III-IV
  • Uncontrolled grade 3 arterial hypertension (SBP ≥180 and/or DBP ≥110 mmHg)
  • Acute cerebrovascular accident, myocardial infarction, surgical interventions, clinically significant injuries within 6 months
  • Internal carotid artery stenosis \>60% and/or symptomatic stenosis 50-99%
  • Chronic obstructive pulmonary disease and bronchial asthma
  • Exacerbation and decompensation of chronic diseases within 1 month ALT and/or AST levels \>2-3 times upper limit of normal
  • Congenital heart and major vessel abnormalities
  • Implanted cardiac pacemaker
  • Cancer with remission \<5 years
  • Mental illness, drug addiction, alcohol dependence
  • Pregnancy
  • Inability to participate throughout the study period

The study team makes the final eligibility decision.

Where it's taking place

  • Moscow, Russia

Compensation & support

Compensation mentioned.

ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.

Questions & answers

Do participants get paid in this trial?

This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 50 years to 74 years. The study team makes the final eligibility decision.

Where is this trial taking place?

Study sites include Moscow, Russia. Enter your location above to see the nearest site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.